review · 2015
Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure
Results of phase I and phase II studies demonstrate that omecamtiv mecarbil is safe and well tolerated both as an intravenous and oral formulation. In health...
46 citationsDOI: https://doi.org/10.1517/13543784.2016.1123248